Cell-Penetrating Peptides and CRISPR-Cas9: A Combined Strategy for Human Genetic Disease Therapy

Overview

Journal Hum Gene Ther

Specialties Genetics
Pharmacology

Date 2024 Sep 14

PMID 39276086

Authors

Carla Cristina Pedrosa de Lira de Morais

Eduardo Mannarino Correia

Martin Hernan Bonamino

Zilton Farias Meira de Vasconcelos

Affiliations

Soon will be listed here.

Abstract

The advent of clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated nuclease 9 (Cas9) technology has revolutionized the field of genetic engineering, offering unprecedented potential for the targeted manipulation of DNA sequences. Advances in the mechanism of action of the CRISPR-Cas9 system allowed potential applicability for the treatment of genetic diseases. CRISPR-Cas9's mechanism of action involves the use of an RNA guide molecule to target-specific DNA sequences and the Cas9 enzyme to induce precise DNA cleavage. In the context of the CRISPR-Cas9 system, this review covers nonviral delivery methods for gene editing based on peptide internalization. Here, we describe critical areas of discussion such as immunogenicity, emphasizing the importance of safety, efficiency, and cost-effectiveness, particularly in the context of treating single-mutation genetic diseases using advanced editing techniques genetics as prime editor and base editor. The text discusses the versatility of cell-penetrating peptides (CPPs) in forming complexes for delivering biomolecules, particularly ribonucleoprotein for genome editing with CRISPR-Cas9 in human cells. In addition, it emphasizes the promise of combining CPPs with DNA base editing and prime editing systems. These systems, known for their simplicity and precision, hold great potential for correcting point mutations in human genetic diseases. In summary, the text provides a clear overview of the advantages of using CPPs for genome editing with CRISPR-Cas9, particularly in conjunction with advanced editing systems, highlighting their potential impact on clinical applications in the treatment of single-mutation genetic diseases. [Figure: see text].

References

Wu X, Mao S, Ying Y, Krueger C, Chen A . Progress and Challenges for Live-cell Imaging of Genomic Loci Using CRISPR-based Platforms. Genomics Proteomics Bioinformatics. 2019; 17(2):119-128. PMC: 6620262. DOI: 10.1016/j.gpb.2018.10.001. View

Bolhassani A, Jafarzade B, Mardani G . In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides. 2016; 87:50-63. DOI: 10.1016/j.peptides.2016.11.011. View

Liang P, Xie X, Zhi S, Sun H, Zhang X, Chen Y . Genome-wide profiling of adenine base editor specificity by EndoV-seq. Nat Commun. 2019; 10(1):67. PMC: 6325126. DOI: 10.1038/s41467-018-07988-z. View

Gustafsson O, Radler J, Roudi S, Lehto T, Hallbrink M, Lehto T . Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP. Pharmaceutics. 2021; 13(6). PMC: 8232299. DOI: 10.3390/pharmaceutics13060878. View

Labuhn M, Adams F, Ng M, Knoess S, Schambach A, Charpentier E . Refined sgRNA efficacy prediction improves large- and small-scale CRISPR-Cas9 applications. Nucleic Acids Res. 2017; 46(3):1375-1385. PMC: 5814880. DOI: 10.1093/nar/gkx1268. View

Silva G, Poirot L, Galetto R, Smith J, Montoya G, Duchateau P . Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther. 2010; 11(1):11-27. PMC: 3267165. DOI: 10.2174/156652311794520111. View

Jansen R, van Embden J, Gaastra W, Schouls L . Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002; 43(6):1565-75. DOI: 10.1046/j.1365-2958.2002.02839.x. View

Choi J, Dang Y, Abraham S, Ma H, Zhang J, Guo H . Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther. 2016; 23(7):627-33. DOI: 10.1038/gt.2016.27. View

Xu H, Xiao T, Chen C, Li W, Meyer C, Wu Q . Sequence determinants of improved CRISPR sgRNA design. Genome Res. 2015; 25(8):1147-57. PMC: 4509999. DOI: 10.1101/gr.191452.115. View

10.

Sung P, Klein H . Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat Rev Mol Cell Biol. 2006; 7(10):739-50. DOI: 10.1038/nrm2008. View

11.

Komor A, Kim Y, Packer M, Zuris J, Liu D . Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533(7603):420-4. PMC: 4873371. DOI: 10.1038/nature17946. View

12.

Ran F, Cong L, Yan W, Scott D, Gootenberg J, Kriz A . In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015; 520(7546):186-91. PMC: 4393360. DOI: 10.1038/nature14299. View

13.

Wu H, Hu C, Dang D, Guo Y . A Novel WASP Gene Mutation in a Chinese Boy with Wiskott-Aldrich Syndrome. Indian J Hematol Blood Transfus. 2014; 30(Suppl 1):353-5. PMC: 4192215. DOI: 10.1007/s12288-014-0403-3. View

14.

Anders C, Niewoehner O, Duerst A, Jinek M . Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature. 2014; 513(7519):569-73. PMC: 4176945. DOI: 10.1038/nature13579. View

15.

Frankel A, Pabo C . Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988; 55(6):1189-93. DOI: 10.1016/0092-8674(88)90263-2. View

16.

Xu X, Wan T, Xin H, Li D, Pan H, Wu J . Delivery of CRISPR/Cas9 for therapeutic genome editing. J Gene Med. 2019; 21(7):e3107. DOI: 10.1002/jgm.3107. View

17.

Holkers M, Maggio I, Henriques S, Janssen J, Cathomen T, Goncalves M . Adenoviral vector DNA for accurate genome editing with engineered nucleases. Nat Methods. 2014; 11(10):1051-7. DOI: 10.1038/nmeth.3075. View

18.

Xie H, Tang L, He X, Liu X, Zhou C, Liu J . SaCas9 Requires 5'-NNGRRT-3' PAM for Sufficient Cleavage and Possesses Higher Cleavage Activity than SpCas9 or FnCpf1 in Human Cells. Biotechnol J. 2018; 13(3):e1800080. DOI: 10.1002/biot.201800080. View

19.

Foss D, Muldoon J, Nguyen D, Carr D, Sahu S, Hunsinger J . Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes. Nat Biomed Eng. 2023; 7(5):647-660. PMC: 10129304. DOI: 10.1038/s41551-023-01032-2. View

20.

DAstolfo D, Pagliero R, Pras A, Karthaus W, Clevers H, Prasad V . Efficient intracellular delivery of native proteins. Cell. 2015; 161(3):674-690. DOI: 10.1016/j.cell.2015.03.028. View